

STAND. COM. REP. NO.

1716

Honolulu, Hawaii

APR 02 2019

RE: S.C.R. No. 104  
S.D. 1

Honorable Ronald D. Kouchi  
President of the Senate  
Thirtieth State Legislature  
Regular Session of 2019  
State of Hawaii

Sir:

Your Committee on Commerce, Consumer Protection, and Health,  
to which was referred S.C.R. No. 104 entitled:

"SENATE CONCURRENT RESOLUTION REQUESTING THAT THE AUDITOR  
CONDUCT A SUNRISE ANALYSIS OF MANDATING HEALTH CARE COVERAGE  
FOR CANNABIDIOL OIL DERIVED FROM INDUSTRIAL HEMP,"

begs leave to report as follows:

The purpose and intent of this measure is to request the  
Auditor to assess the social and financial effects of mandating  
health care coverage of cannabidiol oil derived from industrial  
hemp.

Your Committee received testimony in support of this measure  
from the Kihei Community Association and three individuals.

Your Committee finds that industrial hemp contains  
cannabidiol, a therapeutic non-psychoactive chemical compound.  
The medicinal benefits of cannabidiol have been recently  
recognized by the United States Food and Drug Administration,  
which recently approved a cannabidiol oral solution to treat  
seizures associated with severe forms of epilepsy. Additional  
medicinal benefits can include relieving pain, reducing nausea,  
easing migraines, and reducing inflammation. Your Committee  
further notes that industrial hemp-derived products have been  
removed from Schedule I of the federal Controlled Substances Act  
under certain circumstances. H.B. No. 20, introduced during the



Regular Session of 2019, requires health insurers and similar entities that provide coverage for health care to provide drug coverage for cannabidiol oil that is derived from industrial hemp. This measure requests that the Auditor conduct an assessment pursuant to sections 25-51 and 23-52, Hawaii Revised Statutes, to assess the social and financial effects of mandating health care coverage of cannabidiol oil derived from industrial hemp.

Your Committee has amended this measure by:

- (1) Clarifying that industrial hemp-derived products have been removed from Schedule I of the federal Controlled Substances Act under certain circumstances;
- (2) Updating its title to reflect the amended purpose; and
- (3) Making technical, nonsubstantive amendments for the purposes of clarity and consistency.

As affirmed by the record of votes of the members of your Committee on Commerce, Consumer Protection, and Health that is attached to this report, your Committee concurs with the intent and purpose of S.C.R. No. 104, as amended herein, and recommends its adoption in the form attached hereto as S.C.R. No. 104, S.D. 1.

Respectfully submitted on  
behalf of the members of the  
Committee on Commerce, Consumer  
Protection, and Health,




---

ROSALYN H. BAKER, Chair



The Senate  
Thirtieth Legislature  
State of Hawai'i

**Record of Votes**  
**Committee on Commerce, Consumer Protection, and Health**  
**CPH**

Bill / Resolution No.:*	Committee Referral:	Date:		
SCR 104	CPH	3/21/19		
<input type="checkbox"/> The Committee is reconsidering its previous decision on this measure. If so, then the previous decision was to: _____				
The Recommendation is:				
<input type="checkbox"/> Pass, unamended 2312 <input checked="" type="checkbox"/> Pass, with amendments 2311 <input type="checkbox"/> Hold 2310 <input type="checkbox"/> Recommit 2313				
Members	Aye	Aye (WR)	Nay	Excused
BAKER, Rosalyn H. (C)	✓			
CHANG, Stanley (VC)	✓			
KEOHOKALOPE, Jarrett				✓
NISHIHARA, Clarence K.	✓			
RUDERMAN, Russell E.	✓			
THIELEN, Laura H.	✓			
FEVELLA, Kurt	✓			
<b>TOTAL</b>	6			1
Recommendation: <input checked="" type="checkbox"/> Adopted <input type="checkbox"/> Not Adopted				
Chair's or Designee's Signature: 				
<b>Distribution:</b> Original     Yellow     Pink     Goldenrod File with Committee Report     Clerk's Office     Drafting Agency     Committee File Copy				

\*Only one measure per Record of Votes